A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?
Frontiers in Pharmacology · 26.10.2023 · 14
DOI: 10.3389/fphar.2023.1259908 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 26.10.2023. Verfasst von Zhiwei Cui und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Etoposide is a broad-spectrum antitumor drug that has been extensively studied in clinical trials. However, limited information is available regarding its real-world adverse reactions. Therefore, this study aimed to assess and evaluate etoposide-related adverse events in a real-world setting by using data mining method on the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database.
Methods
Through the analysis of 16,134,686 reports in the FAERS database, a total of 9,892 reports of etoposide-related adverse drug events (ADEs) were identified. To determine the significance of these ADEs, various disproportionality analysis algorithms were applied, including the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN), and the multi-item gamma Poisson shrinker (MGPS) algorithms.
Results
As a result, 478 significant disproportionality preferred terms (PTs) that were identified by all four algorithms were retained. These PTs included commonly reported adverse events such as thrombocytopenia, leukopenia, anemia, stomatitis, and pneumonitis, which align with those documented in the drug’s instructions and previous clinical trials. However, our analysis also uncovered unexpected and significant ADEs, including thrombotic microangiopathy, ototoxicity, second primary malignancy, nephropathy toxic, and ovarian failure. Furthermore, we examined the time-to-onset (TTO) of these ADEs using the Weibull distribution test and found that the median TTO for etoposide-associated ADEs was 10 days (interquartile range [IQR] 2–32 days). The majority of cases occurred within the first month (73.8%) after etoposide administration. Additionally, our analysis revealed specific high-risk signals for males, such as pneumonia and cardiac infarction, while females showed signals for drug resistance and ototoxicity.
Discussion
These findings provide valuable insight into the occurrence of ADEs following etoposide initiation, which can potentially support clinical monitoring and risk identification efforts.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
- Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi, China.
- Department of General Medicine, Yanan University Affiliated Hospital, Yan'an, China.
Zitieren
APA
Cui, Z., Cheng, F., Wang, L., Zou, F., Pan, R., Tian, Y., Zhang, X., She, J., Zhang, Y., & Yang, X. (2023). A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1259908
Vancouver
Cui Z, Cheng F, Wang L, Zou F, Pan R, Tian Y, et al. A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1259908
BibTeX
@article{Cui2023,
author = {Cui, Zhiwei and Cheng, Feiyan and Wang, Lihui and Zou, Fan and Pan, Rumeng and Tian, Yuhan and Zhang, Xiyuan and She, Jing and Zhang, Yidan and Yang, Xinyuan},
title = {A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?},
journal = {Frontiers in Pharmacology},
year = {2023},
volume = {14},
doi = {10.3389/fphar.2023.1259908}
}
EUVIMED